Rodin Therapeutics Appoints Adam J. Rosenberg As Chief Executive Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Rodin Therapeutics, a biotechnology company applying insights from epigenetics to develop novel therapeutics for neurological disorders, today announced that its Board of Directors has appointed Adam J. Rosenberg as Chief Executive Officer. Mr. Rosenberg brings almost 20 years of entrepreneurial and transactional leadership, and will also be appointed to Rodin’s Board of Directors.

Help employers find you! Check out all the jobs and post your resume.